公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Liu, Yi-Nan; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; BIN-CHI LIAO ; Hsu, Chia-Chi; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 15 | 15 | |
2013 | ATLAS: Randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer | Johnson B.E; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin C.-Y; Marsland T; Patel T; Polikoff J; Rubin M; White L; CHIH-HSIN YANG ; Bowden C; Miller V. | Journal of Clinical Oncology | 153 | 139 | |
1992 | Autologous bone marrow transplantation for plasma cell leukemia: Report of a case | CHIH-HSIN YANG ; Lin M.-T.; WOEI TSAY ; Liu L.T.; Wang C.-H.; YAO-CHANG CHEN | Transplantation Proceedings | 8 | 4 | |
2021 | Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial | Park, Keunchil; Özgüroğlu, Mustafa; Vansteenkiste, Johan; Spigel, David; CHIH-HSIN YANG ; Ishii, Hidenobu; Garassino, Marina; de Marinis, Filippo; Szczesna, Aleksandra; Polychronis, Andreas; Uslu, Ruchan; Krzakowski, Maciej; Lee, Jong-Seok; Calabrò, Luana; Arén Frontera, Osvaldo; Xiong, Huiling; Bajars, Marcis; Ruisi, Mary; Barlesi, Fabrice | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 30 | 27 | |
2024 | Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial | Reck, Martin; Barlesi, Fabrice; CHIH-HSIN YANG ; Westeel, Virginie; Felip, Enriqueta; Özgüroğlu, Mustafa; Dols, Manuel Cobo; Sullivan, Richard; Kowalski, Dariusz M; Andric, Zoran; Lee, Dae Ho; Sezer, Ahmet; Hu, Ping; Wang, XiaoZhe; von Heydebreck, Anja; Jacob, Natalia; Mehr, Keyvan Tadjalli; Park, Keunchil | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 0 | | |
2016 | AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases | Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim D.-W; Ahn M.-J; CHIH-HSIN YANG ; Zhang X. | Science Translational Medicine | 82 | 28 | |
2015 | AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer | Jänne P.A; Chih-Hsin CHIH-HSIN YANG ; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. | New England Journal of Medicine | 1749 | 1621 | |
1998 | Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity | Kuo M.-L.; Shen S.-C.; CHIH-HSIN YANG ; Chuang S.-E.; ANN-LII CHENG ; Huang T.-S. | Oncogene | 39 | 35 | |
2014 | Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer | JIH-HSIANG LEE ; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; YEUN-CHUNG CHANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIA-CHI LIN ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; PAN-CHYR YANG ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 44 | 35 | |
2000 | BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells | CHIH-HSIN YANG ; Schneider E.; Kuo M.-L.; Volk E.L.; Rocchi E.; YAO-CHANG CHEN | Biochemical Pharmacology | 128 | 118 | |
2021 | Benefits and limitations of real-world evidence: Lessons from EGFR mutation-positive non-small-cell lung cancer | Nazha B.; CHIH-HSIN YANG ; Owonikoko T.K. | Future Oncology | 40 | 30 | |
2018 | Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients | Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; WEI-YU LIAO ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG | Clinical Lung Cancer | 16 | 17 | |
2019 | Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment? | CHIH-HSIN YANG | The Lancet Oncology | 3 | 3 | |
2011 | Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS) | Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG ; Mok T.S.K. | Journal of Clinical Oncology | 1256 | 1128 | |
2014 | Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS) | Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; CHIH-HSIN YANG ; Klughammer B; Colburn D; Miller V; Johnson B.E. | Journal of Thoracic Oncology | 16 | 12 | |
2023 | Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results | Gutierrez, Martin; Lam, Wei-Sen; Hellmann, Matthew D; Gubens, Matthew A; Aggarwal, Charu; Tan, Daniel Shao Weng; Felip, Enriqueta; Chiu, Joanne W Y; Lee, Jong-Seok; CHIH-HSIN YANG ; Garon, Edward B; Finocchiaro, Giovanna; Ahn, Myung-Ju; Luft, Alexander; Landers, Gregory A; Basso, Andrea; Ma, Hua; Kobie, Julie; Palcza, John; Cristescu, Razvan; Fong, Lawrence; Snyder, Alexandra; Yuan, Jianda; Herbst, Roy S | Nature medicine | 2 | 0 | |
2023 | Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial | CHIH-HSIN YANG ; Liu, Geoffrey; Lu, Shun; He, Jianxing; Burotto, Mauricio; Ahn, Myung-Ju; Kim, Dong-Wan; Liu, XiaoQing; Zhao, Yanqiu; Vincent, Sylvie; Yin, Jiani; Ma, Xin; Lin, Huamao M; Popat, Sanjay | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 4 | 0 | |
2020 | Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial | Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG ; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garc?a Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.; Gettinger S.N.; Tiseo M.; Lin H.M.; Gupta N.; Hanley M.J.; Ni Q.; Zhang P.; Popat S. | Journal of Clinical Oncology | 235 | 196 | |
2021 | Brigatinib versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial | Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG ; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garcia Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.I.; Gettinger S.N.; Tiseo M.; Lin H.M.; Liu Y.; Vranceanu F.; Niu H.; Zhang P.; Popat S. | Journal of Thoracic Oncology | 160 | 119 | |
2018 | Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer | Camidge D.R; Kim H.R; Ahn M.-J; CHIH-HSIN YANG ; Han J.-Y; Lee J.-S; Hochmair M.J; Li J.Y.-C; Chang G.-C; Lee K.H; Gridelli C; Delmonte A; Garcia Campelo R; Kim D.-W; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger S.N; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S. | New England Journal of Medicine | 688 | 556 | |